250 related articles for article (PubMed ID: 28797519)
21. Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment.
Lee C; Lee S; Park E; Hong J; Shin DY; Byun JM; Yun H; Koh Y; Yoon SS
Genome Med; 2022 Sep; 14(1):111. PubMed ID: 36171613
[TBL] [Abstract][Full Text] [Related]
22. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.
Swords RT; Azzam D; Al-Ali H; Lohse I; Volmar CH; Watts JM; Perez A; Rodriguez A; Vargas F; Elias R; Vega F; Zelent A; Brothers SP; Abbasi T; Trent J; Rangwala S; Deutsch Y; Conneally E; Drusbosky L; Cogle CR; Wahlestedt C
Leuk Res; 2018 Jan; 64():34-41. PubMed ID: 29175379
[TBL] [Abstract][Full Text] [Related]
23. Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
Hauge M; Bruserud Ø; Hatfield KJ
Eur J Haematol; 2016 Mar; 96(3):211-21. PubMed ID: 26465810
[TBL] [Abstract][Full Text] [Related]
24. [Key molecular mechanisms associated with cell malignant transformation in acute myeloid leukemia].
Orlova NN; Lebedev TD; Spirin PV; Prassolov VS
Mol Biol (Mosk); 2016; 50(3):395-405. PubMed ID: 27414778
[TBL] [Abstract][Full Text] [Related]
25. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.
Mehta SV; Shukla SN; Vora HH
Neoplasma; 2013; 60(6):666-75. PubMed ID: 23906301
[TBL] [Abstract][Full Text] [Related]
27. 'Did He Who Made the Lamb Make Thee?' New Developments in Treating the 'Fearful Symmetry' of Acute Myeloid Leukemia.
Brumatti G; Lalaoui N; Wei AH; Silke J
Trends Mol Med; 2017 Mar; 23(3):264-281. PubMed ID: 28196625
[TBL] [Abstract][Full Text] [Related]
28. MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target.
Zhang S; Zhang Q; Shi G; Yin J
Biomed Pharmacother; 2018 Jan; 97():1189-1194. PubMed ID: 29136958
[TBL] [Abstract][Full Text] [Related]
29. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Kurtz SE; Eide CA; Kaempf A; Khanna V; Savage SL; Rofelty A; English I; Ho H; Pandya R; Bolosky WJ; Poon H; Deininger MW; Collins R; Swords RT; Watts J; Pollyea DA; Medeiros BC; Traer E; Tognon CE; Mori M; Druker BJ; Tyner JW
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):E7554-E7563. PubMed ID: 28784769
[TBL] [Abstract][Full Text] [Related]
30. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
31. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P
Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672
[TBL] [Abstract][Full Text] [Related]
32. Small molecule inhibitors for acute myeloid leukemia: where is the field heading?
Trippier PC
Future Med Chem; 2017 Sep; 9(13):1453-1456. PubMed ID: 28795593
[No Abstract] [Full Text] [Related]
33. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
[TBL] [Abstract][Full Text] [Related]
34. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Garcia JS; Stone RM
Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
[TBL] [Abstract][Full Text] [Related]
35. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.
Lee SI; Celik S; Logsdon BA; Lundberg SM; Martins TJ; Oehler VG; Estey EH; Miller CP; Chien S; Dai J; Saxena A; Blau CA; Becker PS
Nat Commun; 2018 Jan; 9(1):42. PubMed ID: 29298978
[TBL] [Abstract][Full Text] [Related]
36. Signal transduction in Acute Myeloid Leukemia - Implications for Novel Therapeutic Concepts.
Konig H; Santos CD
Curr Cancer Drug Targets; 2015; 15(9):803-21. PubMed ID: 26278711
[TBL] [Abstract][Full Text] [Related]
37. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
38. Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?
Chung C; Ma H
Pharmacotherapy; 2017 Sep; 37(9):1052-1072. PubMed ID: 28654205
[TBL] [Abstract][Full Text] [Related]
39. Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.
Ojamies PN; Kontro M; Edgren H; Ellonen P; Lagström S; Almusa H; Miettinen T; Eldfors S; Tamborero D; Wennerberg K; Heckman C; Porkka K; Wolf M; Kallioniemi O
Leukemia; 2017 May; 31(5):1048-1058. PubMed ID: 27795554
[TBL] [Abstract][Full Text] [Related]
40. Towards precision medicine for AML.
Döhner H; Wei AH; Löwenberg B
Nat Rev Clin Oncol; 2021 Sep; 18(9):577-590. PubMed ID: 34006997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
